The latest market report published by Credence Research, Inc. “Global Lambert-Eaton Myasthenic Syndrome Market By Treatment (Potassium Channel Blockers (Amifampridine), Cholinesterase Inhibitor (Pyridostigmine), Immune Therapy, Intravenous Immunoglobulin, Plasmapheresis) – Growth, Future Prospects And Competitive Landscape, 2019 – 2027,” the global Lambert-Eaton Myasthenic Syndrome market is expected to expand at a CAGR of 6.7% from 2019 to 2027.
According to the statistics provided by National Organization for Rare Diseases (NORD), the global prevalence rate of Lambert-Eaton Myasthenic Syndrome (LEMS) is around 2.8 per million people. In cases when LEMS is associated with small cell lung cancer (SCLC), it occurs in older patients more in men population in comparison to female. Effective screening and treatment guidelines are being stipulated by healthcare agencies throughout the globe for the treatment of LEMS.
Browse the full report Lambert-Eaton Myasthenic Syndrome Market – Growth, Future Prospects, Competitive Analysis, 2019 – 2027 report at https://www.credenceresearch.com/report/lambert-eaton-myasthenic-syndrome-market
There is no permanent cure for the treatment of LEMS in pediatric patients. The drugs currently prescribed by physicians worldwide are to attenuate the clinical manifestations pertaining to LEMS in adult population. Potassium channel blocker, cholinesterase inhibitor, immune therapy, intravenous immunoglobulin and Plasmapheresis etc. are used for the treatment of LEMS in adult population. The recent USFDA approval and designation of orphan drug and fast track status achieved by amifampridine will be widely utilized for the treatment of LEMS in children aged between 6 to 17 years of age.
North America is reigning the regional segment for Lambert-Eaton Myasthenic Syndrome market representing a share of 39%. Primary factors hold responsible for its global dominance is significant rise in the clinical research activities to cure rare autoimmune disorders like LEMS. As per the research findings of National Organization for Rare Diseases (NORD), there are approximately 400 known cases of LEMs in the United States. Domicile of key players such as Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., Merck & Co., Inc., etc further propel the market growth in North America region. Europe holds 34.5% market share owing to the high incidence rate of LEMS in the European community. Asia Pacific is accounting for 14% share on account of huge population base suffering with small cell lung cancer (SCLC) of whom 40% show remarkable clinical manifestation pertaining to LEMS. Proactive government initiatives by providing huge financial aid to fight against orphan diseases.
Pharmaceutical manufacturers providing medications for the treatment of Lambert-Eaton Myasthenic Syndrome are Allergan, Plc., Biomarin Pharmaceutical, Inc., Catalyst Pharmaceuticals, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithkline, Plc., Jacobus Pharmaceutical Company, Inc., Kawasumi Laboratories, Inc., Merck & Co., Inc., Mitsubishi Pharma Corporation.
Download Free PDF Sample Request: https://www.credenceresearch.com/inquiry-before-buying/59722
Key Market Movements:
- Increasing incidence rate of LEMS in children aged between 6 to 17 years of age
- Recent USFDA approval and designation of orphan drugs and fast track status for the development and sale of amifampridine for treating LEMS in children
- Supportive regulatory environment provided by healthcare agencies worldwide for the treatment of rare autoimmune diseases
By Treatment (2017–2027; US$ Mn)
- Potassium Channel Blockers (Amifampridine)
- Cholinesterase Inhibitor (Pyridostigmine)
- Immune Therapy
- Intravenous Immunoglobulin
Geography Segment (2017–2027; US$ Mn)
- United States
- United Kingdom
- Rest of Europe
- Rest of APAC
- Rest of Latin America
East and Africa (MEA)
- Rest of Middle East and Africa
Do Enquiry before Buying for research report: https://www.credenceresearch.com/inquiry-before-buying/59722